Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience

Abstract Background CDK4/6 inhibitors are primarily used to treat hormone-positive HER-2 negative (HR+/ HER2-) metastatic breast cancer. Although ribociclib is generally well-tolerated, there is limited real-world data on hepatotoxicity associated with its use. Therefore, we evaluated the characteri...

Descripció completa

Dades bibliogràfiques

Autors principals:	Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-11-01
Col·lecció:	BMC Cancer
Matèries:	CDK 4/6 inhibitor Breast cancer Ribociclib Hepatotoxicity Clinical management
Accés en línia:	https://doi.org/10.1186/s12885-025-15181-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!